Particulars (Rupees in Crores.) | Sept-2024 | Jun-2024 | Mar-2024 | Dec-2023 | Sept-2023 |
---|---|---|---|---|---|
Gross Sales | 368.65 | 390.21 | 361.2 | 329.36 | 345.97 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 368.65 | 390.21 | 361.2 | 329.36 | 345.97 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 4.51 | 2.68 | 4 | 7.28 | 9.72 |
Total Income | 373.16 | 392.89 | 365.2 | 336.64 | 355.68 |
Total Expenditure | 333.87 | 348.26 | 333.64 | 307.11 | 330.84 |
PBIDT | 39.29 | 44.63 | 31.56 | 29.53 | 24.85 |
Interest | 14.29 | 16.38 | 12.44 | 12.58 | 12.58 |
PBDT | 25 | 28.25 | 19.12 | 16.95 | 12.27 |
Depreciation | 17.1 | 16.25 | 16.48 | 15.46 | 15.36 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 7.97 | 11.16 | 3.45 | 4.54 | 17.67 |
Deferred Tax | -6.41 | -8.22 | -2.08 | -13.73 | -13.88 |
Reported Profit After Tax | 6.34 | 9.06 | 1.27 | 10.68 | -6.88 |
Minority Interest After NP | 3.73 | 2.55 | 2.19 | 2.41 | 1.5 |
Net Profit after Minority Interest | 2.61 | 6.51 | -0.92 | 8.27 | -8.38 |
Extra-ordinary Items | 0.04 | 0 | -1.26 | -1.78 | -9.6 |
Adjusted Profit After Extra-ordinary item | 2.57 | 6.51 | 0.34 | 10.05 | 1.22 |
EPS (Unit Curr.) | 0.11 | 0.26 | -0.04 | 0.33 | -0.34 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 49.92 | 49.9 | 49.89 | 49.89 | 49.89 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 10.65 | 11.43 | 8.73 | 8.96 | 7.18 |
PBDTM(%) | 6.78 | 7.23 | 5.29 | 5.14 | 3.54 |
PATM(%) | 1.71 | 2.32 | 0.35 | 3.24 | -1.98 |
Viyash manufactures active pharmaceutical ingredients (APIs) and drug formulations for the human health segment.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice